An­oth­er Cipla site lands a Form 483 over clean­ing is­sues and QC con­trols

A Cipla drug man­u­fac­tur­ing site in In­dia has once again land­ed in the crosshairs of FDA in­spec­tors.

The fa­cil­i­ty in ques­tion is Cipla’s drug man­u­fac­tur­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER